2026-10-25
Arteris, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 27,087 +1.72%
S&P 7,401 +0.65%
GOLD $4,073 −1.00%
BTC $75,828 −0.15%
VIX 24.55 −12.88%
latest tape · as of 20:03 UTC
The Screen · Technology · Semiconductors
Arteris, Inc.
AIP · Nasdaq · USD · Market cap $890M · 353 employees
Arteris, Inc., together with its subsidiaries, provides semiconductor system intellectual property (IP) solutions in the United States, rest of the Americas, China, Korea, the rest of the Asia Pacific, Europe, and the Middle East.
Not yet scored15.93 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price15.93 USD at the 5 Nov 2026 close
- Our value readFair vs our fair value, as of 5 Nov 2026
- Our regime readDistribution, as of 5 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 2.21)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $19.53 to $22.45, base estimate $19.53 (screen dated 2026-11-05).
- Trend Distribution
- Insiders insiders sold, $145,500, latest filing 2026-10-05
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.21, read 2026-11-05
- Ethical screen not yet scored
Price15.93 USD
Fair value19.53
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-01Read Distribution18.80-15.3% to today ✓Markdown gives way to Distribution after a 6% slide in 13 days
2026-10-19Read Markdown19.92-20.0% to today ✓Accumulation gives way to Markdown after an 18% slide in 2 weeks
2026-10-02Read Accumulation24.16-34.1% to today Markdown gives way to Accumulation after a 16% rise in 11 days
2026-09-21Read Markdown20.87-23.7% to today ✓Distribution gives way to Markdown after a 26% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Arteris, Inc. holds its Distribution at $15.93. The statistical read favours the sellers, held for 52 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 52 days |
| Price at the screen | $15.93 |
| Valuation | N/A trailing · 145.63 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.97 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 5.19% | Below 33% | Interest-bearing debt is just 5.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 17.99% | Below 33% | Cash held in interest-bearing accounts and securities is 18.0% of assets, under the one-third limit. | Pass |
| Receivables | 44.68% | Below 49% | Money owed to the company is 44.7% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Arteris, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Arteris, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 5%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 7% discount to our $19.53 fair value, 46.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 18.4% discount to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +139% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $19.53, with a range of $19.53 to $22.45, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business. It trades close to our $19.53 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | 145.6xexpensive even after accounting for its growth |
| EPS, trailing | -0.87 |
| EPS, forward | 0.12 |
| Revenue growth | +46.2%growing very fast |
| Profit margin | -46.7%currently unprofitable |
| Return on equity | -131.4%not currently earning a positive return on equity |
| FCF yield | 3.49% |
| Debt to equity | 0.13minimal debt: a conservative balance sheet |
| Current ratio | 1.57healthy short-term liquidity |
| Beta | 1.97much more volatile than the market |
| Short interest, float | 0.07% |
| 52-week range | 12.06 - 50.26 |
| Market cap | $890M |
| Employees | 353 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAIP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Distribution $18.10
-2.8% Entry 19
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Distribution $18.63
-0.9% Entry 18
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Distribution $18.80
+0.0% Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Distribution $18.80
+0.0% Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Distribution · changed $18.80
-10.3% Entry 15
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Markdown $20.95
+0.0% Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Markdown $20.95
+0.0% Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Markdown $20.95
+0.1% Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Markdown $20.93
+5.1% Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter. Since the last review it dropped out of the Titan Ethical 500.
2026-10-19
Markdown · changed $19.92
-11.2% Entry 10
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (4 analysts) rates it none, with a mean price target of $38. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Why Should You Think About Synopsys Differently Now? Yahoo Finance · 10d ago
- What Just Happened To Synopsys Stock? Yahoo Finance · 11d ago
- Arteris (AIP) Stock Looks Fully Priced On Current Sales Yahoo Finance · 12d ago
- Arteris (AIP) Stock Fair Value Falls As Analysts Weigh Chiplet Growth Potential Yahoo Finance · 16d ago
- Arteris to Announce Financial Results for the Third Quarter 2026 on Thursday, November 5, 2026 Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
POETPOET Technologies Inc.
CEVACEVA, Inc.
AMBQAmbiq Micro, Inc.
WOLFWolfspeed, Inc.
INDIindie Semiconductor, Inc.
AOSLAlpha and Omega Semiconductor Limited
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Alpern Paul L | VP, GC | S - Sale | 6,003 | $145,500 |
| 2026-10-05 | Janac K Charles | Pres, CEO, 10% | S - Sale | 11,452 | $277,987 |
| 2026-10-02 | Moll Laurent R | COO | S - Sale | 17,819 | $434,776 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $33.13 | +1.4% | · | $1,014 | +1.4% |
| 2 months | $19.34 | +73.7% | · | $1,737 | +73.7% |
| 3 months | $14.68 | +128.8% | · | $2,288 | +128.8% |
| 6 months | $19.67 | +70.8% | · | $1,708 | +70.8% |
| 1 year | $8.29 | +305.2% | · | $4,052 | +305.2% |
| 2 years | $8.17 | +311.1% | · | $4,111 | +311.1% |
| 3 years | $7.42 | +352.7% | · | $4,527 | +352.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AIP does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.